text:
North Brunswick officials to US Senate: Pass Daniel's Law
Susan Loyer
Bridgewater Courier News
NORTH BRUNSWICK – The mayor and township council are urging the U.S. Senate to pass legislation to increase security protections for members of the judiciary.
"It is unconscionable that Rand Paul (R-Kentucky) and other members of his caucus would delay measures protecting individuals and the families of those serving our nation as members of the judiciary when the tragic loss of Daniel Anderl is a glaring example as to why we need additional security measures," township officials said in a statement.
The Daniel Anderl Judicial Security and Privacy Act of 2020 is named after the son of U.S. District Court Judge Esther Salas, who was fatally shot in his township home in July.
About 5 p.m. July 19, Anderl and his father, attorney Mark Anderl, went to the door of their township home where a gunman, posing as a delivery person, opened fire, killing Daniel and critically wounding his father.
Judge Salas, who was in another part of the home at the time, was not injured.
The gunman, Roy Den Hollander, 72, of New York, a self-proclaimed anti-feminist attorney who grew up in Bergen County and had a case before Salas, was found dead of a self-inflicted gunshot wound in Rockland County, New York on the day after the slaying.
Following the attack at her home, Salas called for more privacy for federal judges.
In November, Gov. Phil Murphy signed "Daniel's Law," that makes publishing a current or retired judge's home address a crime and creating a framework for civil lawsuits.
The proclamation by the mayor and township council rebukes Paul who blocked a bill sponsored by Sen. Bob Menendez (D-New Jersey) that prevents data brokers from selling or trading personal information of federal judges, as well as providing funding to states to enforce the program.
Paul halted the bill's progress toward a vote by the full Senate because he sought an amendment, to add members of Congress to the legislation
Other members of the Republican Party also opposed the bill because they were not in favor of additional funds for the U.S. Marshall's Service.
More: 'Daniel's Law' now protects New Jersey judges after slaying of Esther Salas' son
More: North Brunswick mayor wants bills to protect judiciary named after Judge Salas' son
"How ironic for a group of politicians, who in large part vilified a segment of our society as a "Me Too" movement suddenly are crying "me too," township officials said in the statement. "The right thing to do would be to move Daniel's Law forward and address the other concerns in separate legislation. We want to make it clear that we stand behind a grieving mother and father, the healing of our township and passage of legislation that goes a long way to accomplishing that and more."
The Daniel Anderl Judicial Security and Privacy Act "is an urgently needed step in providing security for our federal judges and their families," according to a township proclamation.
Email: sloyer@gannettnj.com
Susan Loyer covers Middlesex County and more for MyCentralJersey.com. To get unlimited access to her work, please subscribe or activate your digital account today.


Lib Dem score 50% of vote in by-election win!
Pensioners would be guaranteed to earn at least an extra £790 per year by the end of the next parliament under Liberal Democrat manifesto plans, Pensions Minister Steve Webb has announced.
These changes mean the state pension will be worth at least £131-a-week by 2020, up from just £97.65 four years ago and is expected to benefit nearly 1.5 million pensioners in the South East.


text:
DJ Magnus Podcasts
Melbourne-born & bred, DJ Magnus clearly communicates an infectious passion for music through the decks. If you missed his debut gig at Cairns Tropical Pride in 2007, he may well have had you sweating it out at... Big Gay Day (Brisbane), I Remember House (Sydney / Melbs), Midsumma T-Dance (Melbourne), CoastOut (Coffs Harbour), ChillOut (Daylesford), Christchurch Pride (NZ), Rebel Bar (Melbs / Sydney), Broken Heel Festival (Broken Hill), Geelong Rainbow Festival, Tropical Fruits Festival (Lismore), or... Sydney Gay & Lesbian Mardi Gras AfterParty. His signature sound of uplifting vocal House and an instinct for reading a crowd whilst delivering goosebumps on the dance floor have earned him a respected place as one of Australia's finest House music DJs. However, he also shows fantastic versatility & diversity by playing Deep House and Trance for his fans. He's held residencies all over Australia, including... The Wickham / White Wolf (Brisbane), Daywash / Hot Kandi / ARQ / The Colombian (Sydney), Rock City / Sircuit / The GH / Sundaylicious and Viper Room (Melbourne), and Flamingos (Hobart)...
https://dj-magnus.podomatic.com
HOUSE!
Who's ready to come on a feel good magic carpet ride of "hands in the air" Happy House? Since asking you what genre of mix you'd like me to cook up next, I ducked back to the mid-2000's and threw in 13 of my fave tracks from back then...from Crazibiza to Yazz! Deeeliciously tasty and now ready to serve fresh at your next House party, so crank it up and dance! Peace, love and tunes, Magnus.
2020-05-16 1h10m

redpajama_set_name: RedPajamaCommonCrawl


text:
Journal of Diabetes Mellitus > Vol.11 No.5, November 2021
The Evolution of Insulin Administration in Type 1 Diabetes ()
Catherina T. Pinnaro1,2, Michael J. Tansey1,2*
1University of Iowa Stead Family Department of Pediatrics, Iowa City, USA.
2Fraternal Order of Eagles Diabetes Research Center, Iowa City, USA.
DOI: 10.4236/jdm.2021.115021 PDF HTML XML 40 Downloads 243 Views Citations
Insulin has been utilized in the treatment of type 1 diabetes (T1D) for 100 years. While there is still no cure for T1D, insulin administration has undergone a remarkable evolution which has contributed to improvements in quality of life and life expectancy in individuals with T1D. The advent of faster-acting and longer-acting insulins allowed for the implementation of insulin regimens more closely resembling normal insulin physiology. These improvements afforded better glycemic control, which is crucial for limiting microvascular complications and improving T1D outcomes. Suspension of insulin delivery in response to actual and forecasted hypoglycemia has improved quality of life and mitigated hypoglycemia without compromising glycemic control. Advances in continuous glucose monitoring (CGM) and insulin pumps, efforts to model glucose and insulin kinetics, and the application of control theory to T1D have made the automation of insulin delivery a reality. This review will summarize the past, present, and future of insulin administration in T1D.
Type 1 Diabetes (T1D), Insulin, Hybrid-Closed Loop, Hypoglycemia
Pinnaro, C. and Tansey, M. (2021) The Evolution of Insulin Administration in Type 1 Diabetes. Journal of Diabetes Mellitus, 11, 249-277. doi: 10.4236/jdm.2021.115021.
The discovery, purification, and subsequent demonstration that insulin administration could reduce blood and urine glucose levels and reverse ketoacidosis in individuals with type 1 diabetes (T1D) ultimately changed T1D from a terminal disease into a manageable chronic illness [1] [2]. One hundred years later, there have been significant improvements in T1D outcomes, but there is still no cure for T1D. These improvements were directly facilitated by advancements in insulin delivery (Figure 1). Results from the Diabetes Control and Complications Trial (DCCT) were reported in 1993 and illustrated that intensive insulin therapy, using three or more insulin injections or insulin pump therapy, was effective at reducing long-term complications of diabetes [3]. As a result, life expectancy for individuals with T1D has improved substantially, although is still on average 8 years less than someone without T1D [4] [5].
The DCCT also demonstrated that achieving tighter glycemic targets in adolescents and adults is limited by insulin-induced hypoglycemia [6] [7] [8]. Younger children are likely at an even higher risk of hypoglycemia [9]. Additionally, hypoglycemia and fear of hypoglycemia are barriers to exercise, which itself has glycemic and cardiovascular benefits and reduces mortality [10] - [15]. In the thirty years following the initial DCCT reports, iatrogenic hypoglycemia is still the main limiting factor in achieving normoglycemia in individuals with T1D [16].
Insulin is safely and effectively administered for therapeutic use via intravenous, subcutaneous and inhaled routes [17] [18]. Intravenous insulin is reserved for use in treatment of diabetic ketoacidosis, during major surgery, and in critical illness [19] [20] [21]. Intraperitoneal insulin using implantable pumps or percutaneous port systems is indicated when subcutaneous or inhaled routes are not possible or effective, although this is not widely available outside of Europe [22] [23]. Intramuscular injections should be avoided due to their propensity to precipitate severe hypoglycemia [24] [25]. Oral insulin is currently therapeutically ineffective due to enzymatic degradation by the gut [26]. It continues to be explored for a potential role in delaying or preventing T1D by inducing immune tolerance [27] [28] [29] [30].
2. Updates to Injectable Insulin
The first insulin injections were subcutaneous injections of animal-derived insulin and given to prevent severe metabolic decompensation associated with insulinopenia [1]. The goal of insulin therapy has progressed from preventing coma and death to achieving near-normal glucose levels. This has required modifications to insulin's structure and concentration, which were undertaken almost immediately after therapeutic use of insulin had begun [31]. Modifications to prolong the duration of insulin action were made as early as the 1930s and continue today [32] [33]. Purification processes continued to improve; semi-synthetic insulin, which was less immunogenic than pure animal insulin, was developed in the early 1980s [34]. Recombinant DNA (rDNA) human insulin became a reality shortly after, which resulted in a purer, less immunogenic product and enabled large scale production [35]. Modifications to create rapid acting analog formulations became available in the 1990s and continue to be improved upon today [36].
Basal-bolus therapy is standard-of-care in T1D and can be achieved using regular human insulin or rapid-acting insulin analogs (lispro, aspart, glulisine)
Figure 1. Timeline of important advancements in insulin delivery.
for prandial coverage [37] [38]. Rapid-acting analogs are generally preferred for prandial insulin in multiple daily injection (MDI) regimens as they offer a reduction in hypoglycemia alongside decreased post-prandial blood glucose (BG) [39] [40] [41] [42] [43]. They have an onset of action in 15 to 20 minutes and peak action in 1 - 2 hours [44] [45] [46] [47] [48]. Their pharmacokinetics allow for increased dosing flexibility over older regimens. Additionally, they can be used in traditional insulin pump therapy and hybrid-closed loop (HCL) therapy, described in further detail in sections 3 and 5. The standard U-100 concentrations are available in vials, cartridges, and pre-filled insulin pens [44] [45] [46]. A concentrated form of rapid acting insulin (lispro U-200) exists and can be prescribed as pre-filled pens only [49]. The main benefit of concentrated lispro, which is bioequivalent to U-100 lispro, is the ability to deliver lower volumes of insulin [50]. Lower injected volumes may decrease injection site pain [51].
Basal insulin therapy has undergone a similarly impressive transformation. Neutral protamine Hagedorn (NPH) insulin, lente and ultralente as basal insulin therapy have been improved upon with peakless long and ultra-long-acting basal insulins (detemir, glargine, degludec, discussed in the following paragraph). Adult data demonstrates better glucose control with less hypoglycemia on basal-bolus regimens using the previously discussed rapid-acting analogs with newer long-acting insulin analogs compared to NPH insulin/regular human insulin [52] [53]. Injection regimens with NPH and/or regular human insulin are still used in T1D and have the benefit of decreasing the injection burden and can be employed in situations where children do not have adequate supervision to inject insulin midday [38] [54].
Glargine is an rDNA insulin with modifications made to the amino acid structure that shift the isoelectric point, causing it to precipitate in tissue after injection and extending its duration of action to 24 hours [55]. It comes in both U-100 and U-300 concentrations, with the U-300 concentration demonstrating even longer duration of action and a more even glucodynamic profile compared to U-100 [56]. As such, U-100 and U-300 glargine are not bioequivalent and a direct unit-per-unit conversion may not apply [57]. Detemir is also a modified rDNA insulin with an additional chemical modification (acylation) that allows it to bind to albumin, prolonging its absorption [58]. Smaller doses of detemir appear to last about 20 hours, with higher doses (0.6 to 1.6 U/kg) lasting about 24 hours in adults with T2D [59]. Insulin degludec (Tresiba, NovoNordisk, Bagsvaerd, Denmark) is a new, ultra-long-acting basal insulin with a glucose lowering effect lasting 42 hours after injection [60]. It is also an rDNA insulin with both amino acid substitutions and a chemical modification (acylation via glutamic acid linker) [61]. When compared to insulin glargine, degludec has comparable efficacy but demonstrates less nocturnal hypoglycemia in adults [62] [63]. Nocturnal hypoglycemia and hyperglycemia with ketosis are significantly reduced in pediatric patients when comparing degludec to detemir [64]. Degludec is available in U-100 and U-200 concentrations, which are bioequivalent [65].
Updates to subcutaneous insulin—even faster onset
Rapid-acting insulin analogs, as discussed above, provide significant improvement in insulin delivery, however they are still too slow in onset to match the physiologic insulin secretion pattern in individuals without T1D. They must be taken well in advance of eating to have maximal impact on post-prandial hyperglycemia, which is difficult especially for young children [66]. Faster-acting aspart (Fiasp, NovoNordisk, Bagsvaerd, Denmark), a modified version of aspart, has more rapid onset in the circulation with greater glucose lowering effects during the first 2 hours than traditional aspart [66]. It was approved by the FDA in 2017 for adult use and subsequently was approved for adult use in insulin pumps in 2019 [67]. It has been demonstrated safe and effective in children with T1D [68] and was expanded to pediatric use in 2020 [69]. Ultra-rapid lispro (Lyumjev, Eli Lilly, Indiana, US), a modified version of lispro, has a similarly shifted pharmacokinetic and glucodynamic profile [70]. Ultra-rapid lispro was FDA approved for adults in June 2020 [71]. A phase III trial is expected to conclude in mid 2021 for pediatrics (NCT03740919). Compatibility with insulin pumps has been demonstrated [72], but it is not approved for use in insulin pumps at the time of submitting this paper.
Insulin Pens
Insulin pens were first introduced in 1987 and partially address quality of life and diabetes outcome-related barriers to insulin delivery with vial and syringe (including convenience, dosage, pain, and hypoglycemia) [73]. Insulin pens contain pre-filled insulin, and a pen needle is attached for each injection. Accurate doses of insulin can be easily measured using a dial. The first digital insulin pen, the HumaPen Memoir, debuted in 2007 and allowed recall of the date, time, and recent insulin dosages [74]. The first smart insulin pen (InPen; Companion Medical Inc., San Diego, CA) launched in the US ten years later and syncs to a smartphone application. The application can be programmed with insulin-to-carbohydrate (I:C) ratios, insulin sensitivity factors (ISF), BG targets, and duration of insulin action (DIA) which culminate in dosage suggestions similar to pump bolus calculators. Residual bolus insulin is tracked and accounted for to mitigate insulin stacking. Fixed dosing and meal-estimation can be used in place of I:C ratios in the dose calculator settings. Settings can be varied by time of day [75].
3. Traditional "Open Loop" Insulin Pumps
MDI remains the predominant mode of insulin delivery worldwide, although continuous subcutaneous infusion (CSII) via insulin pump continues to increase and varies widely by age and population [76] [77] [78]. Insulin pumps fall into two broad categories of medical devices: conventional pumps and patch pumps. Conventional pumps have a housing (which contains the insulin, electronics, pump and battery), a subcutaneous catheter, and tubing which connects the insulin pump to the catheter [79]. Patch pumps are worn on the skin and house the insulin and pump mechanisms in a small contained device [79] [80]. Both types of traditional pumps are based on an open-loop insulin delivery system, with no automation of insulin delivery based on BG levels. As such, traditional pumps can be used with or without continuous glucose monitoring (CGM) [80]. An excellent historical review of insulin pumps is provided by Alsaleh et al. [80].
Current traditional insulin pumps allow for settings to be programmed by the provider/user and have built-in bolus calculators, which have demonstrated improvements in glycemic control and patient satisfaction [81] [82]. Programmable settings are similar to the InPen discussed in Section 2 and include insulin-to-carbohydrate (I:C) ratio(s), basal rate(s), duration of insulin action/insulin action time(s) (DIA), insulin sensitivity factor(s) (ISF), and correction target(s) [83] [84] [85] [86]. These settings can be varied throughout the day to account for changes in insulin needs and insulin sensitivity. In traditional pump therapy, DIA is used to calculate the remaining insulin on board at any given time after a bolus [83] [84] [85]. These settings can improve safety in insulin delivery and can help mitigate insulin stacking, which could lead to hypoglycemia. These settings are used to some degree in the various automated insulin delivery systems, which are discussed in sections 5 and 7.
Typical insulin pumps use only rapid-acting or faster-acting rapid-acting insulin. CSII may modestly reduce HbA1c without sufficient evidence to infer improvements in glycemic outcomes such as hypoglycemia when compared to MDI [87]. Several studies cite quality of life improvements on CSII therapy [88] [89] [90]. Additional benefits to CSII include the ability to use extended, dual, or square-wave boluses to more closely mimic absorption of mixed macronutrient content meals [91]. While diabetic ketoacidosis (DKA) is of theoretical concern on CSII given the sole use of rapid-acting insulin, recent studies do not demonstrate significant differences in rates of DKA between CSII and MDI. This risk estimate is limited due to risk of bias in most clinical studies [92] [93]. Real-world data also do not favor increases in DKA in CSII users but may reflect CSII prescribing practices [78].
4. Partial Automation Part 1—Hypoglycemia Mitigation. The Evolution of Low Glucose Suspend (LGS) and Predictive Low Glucose Suspend (PLGS)
Iatrogenic hypoglycemia continues to limit achievement of normoglycemia in T1D [16]. Additionally, fear of hypoglycemia is common in individuals with T1D and parents of children with T1D with significant impact on quality of life [94] and conflicting evidence on glycemic control [95] [96]. Integration of CGM with CSII allowed for low glucose alarms and subsequently the birth of sensor-augmented pump therapy (SAP) systems with low-glucose suspend (LGS). LGS systems suspend insulin delivery when the CGM-reported BG hits a pre-set hypoglycemia threshold. Basal insulin typically remains suspended for a maximum fixed time interval if no action is taken [97]. Studies of LGS demonstrated stable glycemic control with improvements in hypoglycemia [98] [99].
Introduction of algorithms used to forecast future hypoglycemia based on CGM trends and insulin-on-board led to predictive low glucose suspend (PLGS), including the MiniMed 640G (Medtronic, Northridge, California) and the Basal-IQ system (Tandem Inc., San Diego, California) [100] [101]. Basal insulin delivery is shut off when the predicted or actual CGM value reaches a pre-specified hypoglycemia threshold and may remain suspended for a fixed time interval (Basal-IQ, 640G), may stay suspended until the CGM glucose value starts to rise (Basal-IQ), or a future predicted BG is above a pre-specified threshold (Basal-IQ, 640G) depending on the system [100] [101]. PLGS demonstrates benefits over LGS, including less time spent < 70 mg/dL. PLGS also demonstrates reduction in fear of hypoglycemia and improvements in sleep quality while maintaining stable glycemic control [102].
5. Hybrid Closed Loop Systems
5.1. Commercially-Available Hybrid Closed Loop Systems (HCL)
Hybrid closed loop systems (HCL, also called artificial pancreas) are insulin delivery systems that automate insulin delivery in addition to augmenting or suspending insulin for actual or predicted hypoglycemia. They employ algorithms that integrate readings from CGM along with insulin-on-board (with other nuances, out of the scope of this article). The outcome is dynamic modulation of insulin administration to keep BG at a prespecified target or in a prespecified target range. HCL are not completely closed systems, as carbohydrates must still be counted and manually entered by the user. Each system uses a different algorithm running on a different device (i.e., pump or cellphone) and employs different CGM(s). Each system thus has different adjustable settings and reasons for auto mode exits [103]. Commercially-available, soon-to-be-available, and do-it-yourself systems are summarized in Table 1. More details about do-it-yourself systems can be found in section 5.2.
Table 1. Summary of currently and soon-to-be available single hormone hybrid closed loop insulin delivery systems. HCL, hybrid closed loop; BG, blood glucose; CGM, continuous glucose monitor; I:C, insulin-to-carbohydrate ratio; ISF, insulin sensitivity factor; DIA, duration of insulin action; iob, insulin on board; DIY, do-it-yourself; TDD, total daily dose.
The first FDA-approved HCL system available was Minimed 670G (Medtronic, Northridge, California). When in auto mode, automated basal rates are modulated to achieve the preset target. The user/provider can adjust I:C ratios and DIA when in auto mode. The auto mode target is set at 120 mg/dL unless a temporary (exercise) target is set, which raises the target to 150 mg/dL. ISF is autosensed using historical data, so extraneous insulin entries and/or significant variability in insulin sensitivity may affect performance. The pump may recommend a user-initiated bolus if the BG is greater than or equal to 150 mg/dL. Users cannot employ square wave, dual wave, or other types of advanced boluses when in auto mode [84]. The 770G was approved last year with an expanded age indication and allowed for remote data visualization [104]. The 780G is not yet FDA approved but adds in autocorrective boluses with an updated algorithm. It is expected to work with an improved CGM that will only require calibration on the first day of use. The 780G features a default target of 100 mg/dL, with an option to increase to 120 mg/dL. All three MiniMed systems have demonstrated safety and efficacy [105] [106] [107]. Further improvements to hyperglycemia and TIR without increased hypoglycemia are noted when comparing the 780G to the 670G [105] [108]. Real world data from the 670G demonstrates that percentage of time spent in auto mode declined significantly over the first year with a main barrier to usage being CGM-related issues [109] [110].
The Tandem Control-IQ system (Tandem Inc., San Diego, California) has the ability to give automated correction boluses [111]. However, one still must bolus for meals. In normal Control-IQ mode, user/provider-set basal rates are adjusted to keep BGs in the target range of 112.5 - 160 mg/dL. Insulin delivery is suspended if BG is predicted to go below 70 mg/dL 30 minutes into the future or does go below 70 mg/dL. Automatic corrections are given if BG is predicted to be above 180 mg/dL in the next 30 minutes and are given up to once per hour using a correction target of 110 mg/dL. Sixty percent of the predicted insulin correction is administered with automatic correction boluses. The ISF can be adjusted by the user/provider—ISF, IOB, and TDD drive the algorithm's maximum insulin delivery rate calculation. Extended boluses can be set for 2 hours duration in Control-IQ mode. The user can enable activity modes (i.e., sleep or exercise) which modify the BG target range. No automatic boluses are given during sleep mode [83]. Pivotal trials using Control-IQ demonstrated safety and efficacy as compared to SAP in children and adults, with significant improvements in TIR and HbA1c [111] [112]. Adults also saw decreased hypoglycemia [111]. Median percent time in automation remained over 90% at one year of real world use with this system [113].
Omnipod (Insulet Corporation, Boston, Massachusetts) has completed their pivotal trial for the Omnipod 5 automated glucose control system (NCT04196140) in individuals aged 6 - 70. Data are pending FDA review, but currently available data demonstrate improvements in HbA1c and TIR in pediatric and adult participants, with adults also demonstrating a decreased time spent in hypoglycemia [114]. Free-living trials have also demonstrated safety and efficacy of this system [115]. Benefits of this system include tubeless automated insulin delivery and adjustable BG targets that can be varied by time of day [116].
The CamAPS system is the only HCL system currently approved for use in pregnancy, receiving a CE mark for use in 2020 [117]. A thorough review of commercially available hybrid closed-loop systems in the UK provides additional details on the CamAPS FX system (CamDiab Ltd., Cambridge, UK) [118] [119] [120]. The DBLG1 system (Diabeloop, Grenoble, France) recently completed a real-world efficacy trial with promising results [121]. Additional details about the system can be found in the pilot study (Benhamou et al.) [122].
There are other HCL algorithms in development, both in academic and commercial settings. It is beyond the scope of this article to review them all in detail. Some of these include dual hormone (i.e., insulin and glucagon) algorithms, which are briefly reviewed in section 7. Beta Bionic's iLet (Beta Bionics, Boston, Massachusetts, USA), which has single and dual hormone options has an ongoing phase 3 clinical trial (NCT04200313) for the insulin-only version of their pump, and enrolled adults and children age 6+. The SAFE-AP system is a single-hormone HCL controller that includes carbohydrate recommendations as an additional control input. This can be used with both announced and unannounced exercise and has been demonstrated to maintain BGs within target range after both unannounced and announced heavy physical activity. This algorithm is programmed to ensure that the counter-regulatory effect of the rescue carbohydrates does not trigger additional insulin release [123].
5.2. Do-It-Yourself (DIY) Hybrid Closed Loop Systems
Frustrated with the pace of discovery, unaffordability, and lack of customization, the #WeAreNotWaiting movement developed do-it-yourself artificial pancreas systems (DIYAPS) [124]. The three main DIYAPS systems include OpenAPS (algorithm runs on a small computer), AndroidAPS (algorithm runs on an android phone, same base algorithm as OpenAPS), and Loop (algorithm runs on an iPhone and uses a hardware radio bridge communication device). The FreeAPS branch of Loop, which offered some unique features, has been frozen as the developers work on a new DIYAPS called FreeAPS X [125]. Similar to the commercially-available systems, the algorithms collect and analyze data related to glucose, insulin, and carbohydrates to predict future glucose levels and automate insulin delivery in response. There are additional customizations and forked branches. A comprehensive review of these systems is provided by Kesavadev et al. [126]. At the of the time of article submission, over 2200 people worldwide were using DIYAPS [127].
The Loop Observational Study (NCT03838900) recently completed after enrolling 1212 participants using Loop. They collected device data via Tidepool (Tidepool Project, Palo Alto, California), HbA1c, self-reported adverse events, self-reported device issues, and psychosocial/user experience data. Interval data were presented at the Advanced Technologies and Treatments for Diabetes meeting in 2020 on 873 Loop users. The baseline mean TIR for users was fairly high at 67% but improved significantly to 73% with corresponding reductions in HbA1c. They reported low baseline and follow up hypoglycemia rates with additional improvements in diabetes distress, fear of hypoglycemia, and sleep quality [128]. Tidepool has adapted the Loop app for commercial use as an interoperable glycemic controller, meaning their application will work across platforms with multiple insulin pumps and CGMs [129]. The 510(k) was submitted to FDA in December 2020 using data from the aforementioned Loop Observational Study [128]. In silico trials of the OpenAPS algorithm using University of Virginia's Padova T1D simulator demonstrated safety and efficacy, with optimal performance using the automated bolus version (oref1 algorithm) [130]. There are few randomized control trials evaluating DIYAPS, but an OpenAPS repository includes promising real-world data [127]. A randomized clinical trial of AndroidAPS (the CREATE trial), comparing this to SAP therapy is underway. An excellent review on outcomes of DIYAPS studies is provided by Jennings et al. [131].
6. Technosphere Inhaled Insulin
Inhaled human insulin (Afrezza, Valencia, California) was approved in 2014 for adults with diabetes as an alternative prandial insulin. It follows Exubera (Pfizer, New York, NY, USA), which is an inhaled insulin approved in 2006. Production of Exubera was voluntarily discontinued shortly thereafter due to low sales [132]. Safety and pharmacokinetic studies of Afrezza in pediatric patients were recently completed in children aged 8 - 17 in two age cohorts (NCT02527625) but it is not yet approved for pediatric use. Afrezza comes in cartridges that can be dosed in 4-unit increments [133]. Multiple cartridges are required for doses exceeding 12U. Spirometry is required prior to initiation of therapy as it is contraindicated in patients with chronic lung disease. Afrezza has an onset of action of less than 15 minutes with a mean peak action of 50 minutes in adults [133]. The duration of action varies by dose, ranging from 90 minutes with smaller doses to 270 minutes at larger doses [133]. Individuals report improved satisfaction and quality of life using inhaled insulin as compared to injectable insulin [134] [135]. Inhaled insulin has been associated with lower weight gain in type 2 diabetes and less hypoglycemia compared to subcutaneous insulin but generally demonstrates lower glycemic efficacy compared to subcutaneous insulin therapy [136]. Studies using CGM to monitor glycemia in T1D using inhaled insulin are sparse as are long-term trials evaluating glycemia [18]. The most common pulmonary symptom associated with use of inhaled insulin is non-productive cough [136]. A recent study comparing pre-prandial doses of inhaled insulin versus subcutaneous CSII insulin boluses in conjunction with HCL therapy have demonstrated improvements in early glycemic excursions with utilization of inhaled insulin, consistent with its glucodynamic action. Additional research is needed to determine efficacy, safety, and patient satisfaction of this inhaled/HCL combination insulin dose strategy [137].
7. The Future of Insulin Administration—Insulin Adjuncts, Additional Improvements to Insulin, Complete Closed Loop, Dual-Hormone Pumps
Sodium-glucose cotransporter (SGLT) inhibitors
SGLT-2 is present in the proximal tubule of the kidney, and SGLT-1 is present in both the kidneys and the intestine. SGLT inhibitors are a class of oral medication that eliminate glucose reabsorption in either or both of these transporters, which increases urinary glucose excretion, decreases intestinal glucose absorption, and as such decrease BG in an insulin-independent manner [138]. Results of the EASE, DEPICT, and in Tandem trials demonstrated that selective SLGT2 inhibitors are effective adjuncts for glucose lowering therapy in adults with T1D [139] [140] [141]. These trials also noted improved weight loss without hypoglycemia. The major concern in the use of SGLT inhibitors is euglycemic DKA, postulated to occur via a starvation mechanism [142]. Meta-analysis of SGLT inhibitors in T1D have similarly demonstrated efficacy, with primary adverse events being DKA and genital infections [143]. Continuous ketone monitoring would allow for safer utilization of SGLT agonists, facilitate the safe use of very-low carb diets, as well as provide adjunctive data to closed-loop algorithms. Microneedle technology employing a NAD-dependent dehydrogenase-based electrochemical biosensor has demonstrated the ability to detect real-time levels of β-hydroxylbutyrate along with glucose and lactate [144].
Insulin updates
The most common cause of DKA is insulin non-adherence, and current insulin regimens are cumbersome [145]. Simplified treatment regimens have shown improvements in patient-reported outcomes in type 2 diabetes, but direct studies in T1D are difficult due to the necessity of insulin therapy [146]. Once-weekly insulin treatment with insulin icodec was demonstrated to be effective at lowering HbA1c levels in adults with type 2 diabetes [147]. Phase 3 trials of insulin icodec compared to degludec are being studied in adults with type 1 diabetes (NCT04848480). Weekly insulin for T1D may offer improvements in quality of life and decrease DKA due to insulin omission. The biggest weakness to weekly-dosed insulin is the inflexibility of dosing, which has major implications in active and growing individuals. This may make icodec of limited benefit for the pediatric population, who is likely to benefit most from simplifying insulin delivery.
Hybrid closed-loop and fully closed loop insulin pump therapy
Current rapid acting insulin formulations do not have fast enough onset to allow for completely successful total automation. Simple meal announcement without carbohydrate counting using insulin-only strategies may alleviate some of the mental burden of T1D and improve glycemic outcomes and quality of life. Use of faster-acting insulin analogs discussed above in HCL is underway [148] [149] [150] [151]. Faster acting insulins could potentially allow for simplification of meal bolusing or elimination of meal announcement all together [152]. DIY options (i.e. OpenAPS's advanced dosing features) already exist for unannounced meals [153]. Dual-hormone systems, discussed immediately below, may also make full automation possible.
Dual-hormone closed-loop therapy (insulin/glucagon)
The advent of liquid stable glucagon has enabled dual hormone (DH) closed-loop systems to become achievable [154] [155] [156]. Several research groups are working on automated DH algorithms and devices, which administer both insulin and glucagon [157] [158] [159] [160] [161]. Early feasibility studies show promise for both improved glycemic control as well as hypoglycemia mitigation over PLGS and HCL systems including in situations with a propensity to trigger hypoglycemia, such as exercise [162] [163]. In addition to hypoglycemia, DH algorithms show promise in eliminating precise carbohydrate counting although do seem to operate best when using simple meal announcements with estimated meal size [162]. Adverse outcomes of using micro-doses of glucagon primarily include nausea, vomiting, and headache [164].
Other dual-hormone options (pramlintide/insulin, GLP-1 agonists/insulin)
Pramlintide, an analogue of amylin, can be co-injected with insulin to delay gastric emptying and suppress glucagon secretion and has been demonstrated to improve post-prandial hyperglycemia in T1D. Pramlintide co-administration with rapid-acting insulin in HCL systems has been demonstrated to mitigate meal-related glycemic excursions [165]. Co-administration of faster-acting insulin aspart and pramlintide with only simple meal announcement demonstrated feasibility, and the results of the non-inferiority trial to HCL with standard carbohydrate counting completed in February 2020 (NCT02814123) [152]. Liraglutide, a GLP-1 agonist, may reduce post-prandial glucose excursions and HbA1c in T1D but also may increase hypoglycemia and ketosis [166] [167], making it unlikely to gain widespread use in T1D management.
Improvements for exercise
Management of T1D and exercise remains challenging due to increases in insulin sensitivity and increased insulin-independent glucose uptake into muscles which can persist long after the exercise has completed [168] [169] [170]. DH-closed loop systems discussed above show promise in mitigating early and late-onset exercise-induced hypoglycemia in T1D [157] [171] [172]. Incorporation of heart-rate detection, and lactate and ketone levels into closed-loop algorithms may also help overcome challenges associated with exercise and T1D [144] [173] [174] [175] [176].
8. Caveats
Despite significant advancements in insulin and related diabetes technology, a minority of patients with T1D are meeting the glycemic targets known to reduce complications [78]. Further work needs to be done to explore barriers to achievement of these goals, especially in the adolescent population who have seen worsening glycemic control despite increasing technology uptake [78].
Additionally, equity in diabetes care and care delivery needs to be addressed, as related variables are often absent from trials [92]. Despite an overall rise in insulin pump use (which is associated with improvements in quality of life), non-Hispanic Black youth, Hispanic youth, and American Indian/Alaskan Native youth are significantly less likely to be on insulin pump therapy independent of socioeconomic status [177]. CGM in conjunction with CSII, especially when accounting for PLGS and HCL functionality have demonstrated superiority in many studies and highlights the need to understand and address this inequity [178].
Addressing socioeconomic barriers will also be crucial as the management of T1D continues to evolve. The cost of insulin can be prohibitive [179]. Rapid acting analogs are cost-effective in the treatment of T1D however may be unattainable for uninsured patients [180] [181]. Heterogeneity exists in reimbursement for diabetes technology [182]. As such, patients and their families may have difficulties accessing more advanced diabetes features. Pre-existing gaps in diabetes care and outcomes are likely to widen [183] [184]. Advanced diabetes devices are difficult to learn, maintain and manage, and different educational frameworks will be needed to allow for a wide spectrum of users to achieve success. Mentorship programs and telehealth show promise in addressing health disparities in T1D [185] [186]. Further research in optimal education and care delivery are necessary as diabetes technology becomes more advanced.
Insulin administration has evolved dramatically over the last 100 years. However, with no imminent cure for T1D, further optimization of insulin delivery is necessary. Iatrogenic hypoglycemia is still therapeutically problematic and impairs quality of life. Automated insulin delivery shows great promise in helping patients achieve glycemic targets while mitigating hypoglycemia, but is not perfect nor universally accessible. Research is necessary to identify and rectify barriers to uptake and continued utilization of more advanced methods of insulin administration. More robust head-to-head comparisons of automated insulin delivery methods using representative populations in real-world conditions as well as pragmatic trials will facilitate further improvements and allow for a more patient-centered approach to T1D.
CTP and MJT conceptualized and wrote the first draft of the manuscript. All authors have read and agreed to the published version of the manuscript.
This research was funded by K12 HD027748.
In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).
[1] Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. and Fletcher, A.A. (1922) Pancreatic Extracts in the Treatment of Diabetes Mellitus. Canadian Medical Association Journal, 12, 141-146.
[2] Banting, F.G., Campbell, W.R. and Fletcher, A.A. (1923) Further Clinical Experience with Insulin (Pancreatic Extracts) in the Treatment of Diabetes Mellitus. BMJ, 1, 8-12.
https://doi.org/10.1136/bmj.1.3236.8
[3] Diabetes, C., Complications Trial Research, G., Nathan, D.M., Genuth, S., Lachin, J., Cleary, P., Crofford, O., Davis, M., Rand, L. and Siebert, C. (1993) The Effect of intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. The New England Journal of Medicine, 329, 977-986.
https://doi.org/10.1056/NEJM199309303291401
[4] Miller, R.G., Secrest, A.M., Sharma, R.K., Songer, T.J. and Orchard, T.J. (2012) Improvements in the Life Expectancy of Type 1 Diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study Cohort. Diabetes, 61, 2987-2992.
[5] Heald, A.H., Stedman, M., Davies, M., Livingston, M., Alshames, R., Lunt, M., Rayman, G. and Gadsby, R. (2020) Estimating Life Years Lost to Diabetes: Outcomes from Analysis of National Diabetes Audit and Office of National Statistics Data. Cardiovascular Endocrinology & Metabolism, 9, 183-185.
https://doi.org/10.1097/XCE.0000000000000210
[6] The DCCT Research Group (1991) Epidemiology of Severe Hypoglycemia in the Diabetes Control and Complications Trial. The American Journal of Medicine, 90, 450-459.
https://doi.org/10.1016/0002-9343(91)90605-W
[7] Diabetes Control and Complications Trial Research Group (1994) Effect of Intensive Diabetes Treatment on the Development and Progression of Long-Term Complications in Adolescents with Insulin-Dependent Diabetes Mellitus: Diabetes Control and Complications Trial. The Journal of Pediatrics, 125, 177-188.
[8] The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes, 46, 271-286.
[9] Cengiz, E., Xing, D., Wong, J.C., Wolfsdorf, J.I., Haymond, M.W., Rewers, A., Shanmugham, S., Tamborlane, W.V., Willi, S.M., Seiple, D.L., et al. (2013) Severe Hypoglycemia and Diabetic Ketoacidosis among Youth with Type 1 Diabetes in the T1D Exchange Clinic Registry. Pediatric Diabetes, 14, 447-454.
https://doi.org/10.1111/pedi.12030
[10] Brazeau, A.S., Rabasa-Lhoret, R., Strychar, I. and Mircescu, H. (2008) Barriers to Physical Activity among Patients with Type 1 Diabetes. Diabetes Care, 31, 2108-2109.
https://doi.org/10.2337/dc08-0720
[11] Roberts, A.J., Taplin, C.E., Isom, S., Divers, J., Saydah, S., Jensen, E.T., Mayer-Davis, E.J., Reid, L.A., Liese, A.D., Dolan, L.M., et al. (2020) Association between Fear of Hypoglycemia and Physical Activity in Youth with Type 1 Diabetes: The SEARCH for Diabetes in Youth Study. Pediatric Diabetes, 21, 1277-1284.
[12] Jabbour, G., Henderson, M. and Mathieu, M.E. (2016) Barriers to Active Lifestyles in Children with Type 1 Diabetes. The Canadian Journal of Diabetes, 40, 170-172.
https://doi.org/10.1016/j.jcjd.2015.12.001
[13] Herbst, A., Kordonouri, O., Schwab, K.O., Schmidt, F. and Holl, R.W. (2007) Impact of Physical Activity on Cardiovascular Risk Factors in Children with Type 1 Diabetes: A Multicenter Study of 23,251 Patients. Diabetes Care, 30, 2098-2100.
[14] Miller, R.G., Mahajan, H.D., Costacou, T., Sekikawa, A., Anderson, S.J. and Orchard, T.J. (2016) A Contemporary Estimate of Total Mortality and Cardiovascular Disease Risk in Young Adults with Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care, 39, 2296-2303.
[15] Kriska, A.M., LaPorte, R.E., Patrick, S.L., Kuller, L.H. and Orchard, T.J. (1991) The Association of Physical Activity and Diabetic Complications in Individuals with Insulin-Dependent Diabetes Mellitus: The Epidemiology of Diabetes Complications Study—VII. Journal of Clinical Epidemiology, 44, 1207-1214.
[16] Cryer, P.E. (1994) Hypoglycemia: The Limiting Factor in the Management of IDDM. Diabetes, 43, 1378-1389.
[17] Frid, A.H., Kreugel, G., Grassi, G., Halimi, S., Hicks, D., Hirsch, L.J., Smith, M.J., Wellhoener, R., Bode, B.W., Hirsch, I.B., et al. (2016) New Insulin Delivery Recommendations. Mayo Clinic Proceedings, 91, 1231-1255.
https://doi.org/10.1016/j.mayocp.2016.06.010
[18] Garg, S.K., Mathieu, C., Rais, N., Gao, H., Tobian, J.A., Gates, J.R., Ferguson, J.A., Webb, D.M. and Berclaz, P.Y. (2009) Two-Year Efficacy and Safety of AIR Inhaled Insulin in Patients with Type 1 Diabetes: An Open-Label Randomized Controlled Trial. Diabetes Technology & Therapeutics, 11, S5-S16.
https://doi.org/10.1089/dia.2009.0040
[19] Wolfsdorf, J.I., Glaser, N., Agus, M., Fritsch, M., Hanas, R., Rewers, A., Sperling, M.A. and Codner, E. (2018) ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic Ketoacidosis and the Hyperglycemic Hyperosmolar State. Pediatric Diabetes, 19, 155-177.
[20] Jefferies, C., Rhodes, E., Rachmiel, M., Chizo, A.J., Kapellen, T., Abdulla, M.A. and Hofer, S.E. (2018) ISPAD Clinical Practice Consensus Guidelines 2018: Management of Children and Adolescents with Diabetes Requiring Surgery. Pediatric Diabetes, 19, 227-236.
[21] Pérez, A., Ramos, A. and Carreras, G. (2020) Insulin Therapy in Hospitalized Patients. American Journal of Therapeutics, 27, e71-e78.
https://doi.org/10.1097/MJT.0000000000001078
[22] Rieger, C., Kurz, K., Mueller-Hoffmann, W., Gehr, B. and Liebl, A. (2019) New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion. Journal of Diabetes Science and Technology, 13, 1158-1160.
[23] Spaan, N., Teplova, A., Stam, G., Spaan, J. and Lucas, C. (2014) Systematic Review: Continuous Intraperitoneal Insulin Infusion with Implantable Insulin Pumps for Diabetes Mellitus. Acta Diabetologica, 51, 339-351.
[24] Karges, B., Boehm, B.O. and Karges, W. (2005) Early Hypoglycaemia after Accidental Intramuscular Injection of Insulin Glargine. Diabetic Medicine, 22, 1444-1445.
[25] Frid, A., Gunnarsson, R., Güntner, P. and Linde, B. (1988) Effects of Accidental Intramuscular Injection on Insulin Absorption in IDDM. Diabetes Care, 11, 41-45.
https://doi.org/10.2337/diacare.11.1.41
[26] Arbit, E. and Kidron, M. (2009) Oral Insulin: The Rationale for This Approach and Current Developments. Journal of Diabetes Science and Technology, 3, 562-567.
[27] Krischer, J.P., Schatz, D.A., Bundy, B., Skyler, J.S. and Greenbaum, C.J. (2017) Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients with Type 1 Diabetes: A Randomized Clinical Trial. JAMA, 318, 1891-1902.
https://doi.org/10.1001/jama.2017.17070
[28] Kumar, V., Choudhry, I., Namdev, A., Mishra, S., Soni, S., Hurkat, P., Jain, A. and Jain, D. (2018) Oral Insulin: Myth or Reality. Current Diabetes Reviews, 14, 497-508.
[29] Sosenko, J.M., Skyler, J.S., Herold, K.C., Schatz, D.A., Haller, M.J., Pugliese, A., Cleves, M., Geyer, S., Rafkin, L.E., Matheson, D., et al. (2020) Slowed Metabolic Decline after 1 Year of Oral Insulin Treatment among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. Diabetes, 69, 1827-1832.
[30] Assfalg, R., Knoop, J., Hoffman, K.L., Pfirrmann, M., Zapardiel-Gonzalo, J.M., Hofelich, A., Eugster, A., Weigelt, M., Matzke, C., Reinhardt, J., et al. (2021) Oral Insulin Immunotherapy in Children at Risk for Type 1 Diabetes in a Randomised Controlled Trial. Diabetologia, 64, 1079-1092.
[31] Hirsch, I.B., Juneja, R., Beals, J.M., Antalis, C.J. and Wright, E.E. (2020) The Evolution of Insulin and How It Informs Therapy and Treatment Choices. Endocrine Reviews, 41, 733-755.
https://doi.org/10.1210/endrev/bnaa015
[32] Quianzon, C.C. and Cheikh, I. (2012) History of Insulin. Journal of Community Hospital Internal Medicine Perspectives, 2, Article ID: 18701.
https://doi.org/10.3402/jchimp.v2i2.18701
[33] Gottlieb, P.A. and Michels, A.W. (2020) Advances in Diabetes Treatment—Once-Weekly Insulin. The New England Journal of Medicine, 383, 2171-2172.
https://doi.org/10.1056/NEJMe2031596
[34] Markussen, J., Damgaard, U., Jørgensen, K.H., S	ørensen, E. and Thim, L. (1983) Human Monocomponent Insulin: Chemistry and Characteristics. Acta Medica Scandinavica, 213, 99-105.
[35] Galloway, J.A. (1980) Insulin Treatment for the Early 80s: Facts and Questions about Old and New Insulins and Their Usage. Diabetes Care, 3, 615-622.
https://doi.org/10.2337/diacare.3.5.615
[36] Tibaldi, J.M. (2014) Evolution of Insulin: From Human to Analog. The American Journal of Medicine, 127, S25-S38.
https://doi.org/10.1016/j.amjmed.2014.07.005
[37] American Diabetes Association (2020) Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43, S98-S110.
https://doi.org/10.2337/dc20-S009
[38] Danne, T., Phillip, M., Buckingham, B.A., Jarosz-Chobot, P., Saboo, B., Urakami, T., Battelino, T., Hanas, R. and Codner, E. (2018) ISPAD Clinical Practice Consensus Guidelines 2018: Insulin Treatment in Children and Adolescents with Diabetes. Pediatric Diabetes, 19, 115-135.
[39] Holcombe, J.H., Zalani, S., Arora, V.K. and Mast, C.J. (2002) Comparison of Insulin Lispro with Regular Human Insulin for the Treatment of Type 1 Diabetes in Adolescents. Clinical Therapeutics, 24, 629-638.
[40] Deeb, L.C., Holcombe, J.H., Brunelle, R., Zalani, S., Brink, S., Jenner, M., Kitson, H., Perlman, K. and Spencer, M. (2001) Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children with Diabetes. Pediatrics, 108, 1175-1179.
https://doi.org/10.1542/peds.108.5.1175
[41] Nicolucci, A., Ceriello, A., Di Bartolo, P., Corcos, A. and Orsini Federici, M. (2020) Rapid-Acting Insulin Analogues versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. Diabetes Therapy, 11, 573-584.
[42] Fullerton, B., Siebenhofer, A., Jeitler, K., Horvath, K., Semlitsch, T., Berghold, A., Plank, J., Pieber, T.R. and Gerlach, F.M. (2016) Short-Acting Insulin Analogues versus Regular Human Insulin for Adults with Type 1 Diabetes Mellitus. Cochrane Database of Systematic Reviews, 2016, CD012161.
https://doi.org/10.1002/14651858.CD012161
[43] Melo, K.F.S., Bahia, L.R., Pasinato, B., Porfirio, G.J.M., Martimbianco, A.L., Riera, R., Calliari, L.E.P., Minicucci, W.J., Turatti, L.A.A., Pedrosa, H.C., et al. (2019) Short-Acting Insulin Analogues versus Regular Human Insulin on Postprandial Glucose and Hypoglycemia in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetology & Metabolic Syndrome, 11, Article No. 2.
[44] Lilly, E. (2019) US Prescribing Information—Humalog.
https://pi.lilly.com/us/humalog-pen-pi.pdf
[45] US Prescribing Information—Novolog.
https://www.novo-pi.com/novolog.pdf
[46] US Prescribing Information—Apidra.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021629s015lbl.pdf
[47] Lindholm, A. and Jacobsen, L.V. (2001) Clinical Pharmacokinetics and Pharmacodynamics of Insulin Aspart. Clinical Pharmacokinetics, 40, 641-659.
[48] Becker, R.H. and Frick, A.D. (2008) Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine. Clinical Pharmacokinetics, 47, 7-20.
[49] About Humalog® U-200 KwikPen®.
https://www.humalog.com/u200
[50] de la Peña, A., Seger, M., Soon, D., Scott, A.J., Reddy, S.R., Dobbins, M.A., Brown-Augsburger, P. and Linnebjerg, H. (2016) Bioequivalence and Comparative Pharmacodynamics of Insulin Lispro 200 U/mL Relative to Insulin Lispro (Humalog®) 100 U/mL. Clinical Pharmacology in Drug Development, 5, 69-75.
https://doi.org/10.1002/cpdd.221
[51] Heise, T., Nosek, L., Dellweg, S., Zijlstra, E., Præstmark, K.A., Kildegaard, J., Nielsen, G. and Sparre, T. (2014) Impact of Injection Speed and Volume on Perceived Pain during Subcutaneous Injections into the Abdomen and Thigh: A Single-Centre, Randomized Controlled Trial. Diabetes, Obesity & Metabolism, 16, 971-976.
https://doi.org/10.1111/dom.12304
[52] Hermansen, K., Fontaine, P., Kukolja, K.K., Peterkova, V., Leth, G. and Gall, M.A. (2004) Insulin Analogues (Insulin Detemir and Insulin Aspart) versus Traditional Human Insulins (NPH Insulin and Regular Human Insulin) in Basal-Bolus Therapy for Patients with Type 1 Diabetes. Diabetologia, 47, 622-629.
[53] Monami, M., Marchionni, N. and Mannucci, E. (2009) Long-Acting Insulin Analogues vs. NPH Human Insulin in Type 1 Diabetes. A Meta-Analysis. Diabetes, Obesity & Metabolism, 11, 372-378.
[54] Chase, H.P., Dixon, B., Pearson, J., Fiallo-Scharer, R., Walravens, P., Klingensmith, G., Rewers, M. and Garg, S.K. (2003) Reduced Hypoglycemic Episodes and Improved Glycemic Control in Children with Type 1 Diabetes Using Insulin Glargine and Neutral Protamine Hagedorn Insulin. The Journal of Pediatrics, 143, 737-740.
[55] Heinemann, L., Linkeschova, R., Rave, K., Hompesch, B., Sedlak, M. and Heise, T. (2000) Time-Action Profile of the Long-Acting Insulin analog Insulin Glargine (HOE901) in Comparison with Those of NPH Insulin and Placebo. Diabetes Care, 23, 644-649.
https://doi.org/10.2337/diacare.23.5.644
[56] Becker, R.H., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T. and Heise, T. (2015) New Insulin Glargine 300 Units∙mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared with Insulin Glargine 100 Units∙mL−1. Diabetes Care, 38, 637-643.
[57] Pearson, S.M. and Trujillo, J.M. (2018) Conversion from Insulin Glargine U-100 to Insulin Glargine U-300 or Insulin Degludec and the Impact on Dosage Requirements. Therapeutic Advances in Endocrinology and Metabolism, 9, 113-121.
[58] Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J. and Kurtzhals, P. (2004) The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin. Pharmaceutical Research, 21, 1498-1504.
https://doi.org/10.1023/B:PHAM.0000036926.54824.37
[59] Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L. and Heise, T. (2007) Albumin-Bound Basal Insulin Analogues (Insulin Detemir and NN344): Comparable Time-Action Profiles but Less Variability than Insulin Glargine in Type 2 Diabetes. Diabetes, Obesity & Metabolism, 9, 290-299.
[60] Degludec Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf
[61] Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D.B., Wahlund, P.O. and Ribel, U. (2012) Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-Long-Acting Basal Insulin. Pharmaceutical Research, 29, 2104-2114.
[62] Lane, W., Bailey, T.S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C.T., Nielsen, T.S.S., and Warren, M. (2017) Effect of Insulin Degludec vs. Insulin Glargine U100 on Hypoglycemia in Patients with Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA, 318, 33-44.
https://doi.org/10.1001/jama.2017.7115
[63] Holmes, R.S., Crabtree, E. and McDonagh, M.S. (2019) Comparative Effectiveness and Harms of Long-Acting Insulins for Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes, Obesity & Metabolism, 21, 984-992.
[64] Thalange, N., Deeb, L., Iotova, V., Kawamura, T., Klingensmith, G., Philotheou, A., Silverstein, J., Tumini, S., Ocampo Francisco, A.M., Kinduryte, O., et al. (2015) Insulin Degludec in Combination with Bolus Insulin Aspart Is Safe and Effective in Children and Adolescents with Type 1 Diabetes. Pediatric Diabetes, 16, 164-176.
[65] Korsatko, S., Deller, S., Koehler, G., Mader, J.K., Neubauer, K., Adrian, C.L., Thomsen, H., Haahr, H. and Pieber, T.R. (2013) A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec. Clinical Drug Investigation, 33, 515-521.
[66] Cobry, E., McFann, K., Messer, L., Gage, V., VanderWel, B., Horton, L. and Chase, H.P. (2010) Timing of Meal Insulin Boluses to Achieve Optimal Postprandial Glycemic Control in Patients with Type 1 Diabetes. Diabetes Technology & Therapeutics, 12, 173-177.
[67] Evans, M., Ceriello, A., Danne, T., De Block, C., DeVries, J.H., Lind, M., Mathieu, C., Nørgaard, K., Renard, E. and Wilmot, E.G. (2019) Use of Fast-Acting Insulin Aspart in Insulin Pump Therapy in Clinical Practice. Diabetes, Obesity & Metabolism, 21, 2039-2047.
[68] Bode, B.W., Iotova, V., Kovarenko, M., Laffel, L.M., Rao, P.V., Deenadayalan, S., Ekelund, M., Larsen, S.F. and Danne, T. (2019) Efficacy and Safety of Fast-Acting Insulin Aspart Compared with Insulin Aspart, Both in Combination with Insulin Degludec, in Children and Adolescents with Type 1 Diabetes: The Onset 7 Trial. Diabetes Care, 42, 1255-1262.
[69] Fiasp Announcement.
https://www.ajmc.com/view/fda-approves-fiasp-for-children-with-diabetes
[70] Linnebjerg, H., Zhang, Q., LaBell, E., Dellva, M.A., Coutant, D.E., Hövelmann, U., Plum-Mörschel, L., Herbrand, T. and Leohr, J. (2020) Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial. Clinical Pharmacokinetics, 59, 1589-1599.
[71] Ultra Rapid Lispro Approval.
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lyumjevtm-insulin-lispro-aabc-injection-lillys-new
[72] Bode, B.W., Garg, S.K., Norwood, P., Morales, C., Hardy, T., Liu, R. and Ignaut, D. (2021) Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study. Diabetes Technology & Therapeutics, 23, 41-50.
[73] Lasalvia, P., Barahona-Correa, J.E., Romero-Alvernia, D.M., Gil-Tamayo, S., Castañeda-Cardona, C., Bayona, J.G., Triana, J.J., Laserna, A.F., Mejía-Torres, M., Restrepo-Jimenez, P., et al. (2016) Pen Devices for Insulin Self-Administration Compared with Needle and Vial: Systematic Review of the Literature and Meta-Analysis. Journal of Diabetes Science and Technology, 10, 959-966.
[74] Ignaut, D.A. and Venekamp, W.J. (2007) HumaPen Memoir: A Novel Insulin-Injecting Pen with a Dose-Memory Feature. Expert Review of Medical Devices, 4, 793-802.
https://doi.org/10.1586/17434440.4.6.793
[75] Medical, C. (2021) InPen User Guide.
https://www.companionmedical.com/guides/inpen-user-guide.pdf
[76] Kampmann, U., Madsen, L.R., Bjerg, L., Witte, D.R., Hasselstrøm, K., Østergård, T., Alstrup, K., Møller, M.K., Dylmer, D. and Hansen, K.W. (2018) Prevalence and Geographical Distribution of Insulin Pump Therapy in the Central Denmark Region and Its Association with Metabolic Parameters. Diabetes Research and Clinical Practice, 141, 148-155.
https://doi.org/10.1016/j.diabres.2018.04.042
[77] Gajewska, K.A., Bennett, K., Biesma, R. and Sreenan, S. (2020) Low Uptake of Continuous Subcutaneous Insulin Infusion Therapy in People with Type 1 Diabetes in Ireland: A Retrospective Cross-Sectional Study. BMC Endocrine Disorders, 20, Article No. 92.
[78] Foster, N.C., Beck, R.W., Miller, K.M., Clements, M.A., Rickels, M.R., DiMeglio, L.A., Maahs, D.M., Tamborlane, W.V., Bergenstal, R., Smith, E., et al. (2019) State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technology & Therapeutics, 21, 66-72.
[79] Sora, N.D., Shashpal, F., Bond, E.A. and Jenkins, A.J. (2019) Insulin Pumps: Review of Technological Advancement in Diabetes Management. The American Journal of the Medical Sciences, 358, 326-331.
https://doi.org/10.1016/j.amjms.2019.08.008
[80] Alsaleh, F.M., Smith, F.J., Keady, S. and Taylor, K.M. (2010) Insulin Pumps: From Inception to the Present and toward the Future. Journal of Clinical Pharmacy and Therapeutics, 35, 127-138.
[81] Shashaj, B., Busetto, E. and Sulli, N. (2008) Benefits of a Bolus Calculator in Pre- and Postprandial Glycaemic Control and Meal Flexibility of Paediatric Patients Using Continuous Subcutaneous Insulin Infusion (CSII). Diabetic Medicine, 25, 1036-1042.
[82] Zisser, H., Wagner, R., Pleus, S., Haug, C., Jendrike, N., Parkin, C., Schweitzer, M. and Freckmann, G. (2010) Clinical Performance of Three Bolus Calculators in Subjects with Type 1 Diabetes Mellitus: A Head-to-Head-to-Head Comparison. Diabetes Technology & Therapeutics, 12, 955-961.
[83] Tandem. Control IQ User Guide.
https://www.tandemdiabetes.com/docs/default-source/product-documents/t-slim-x2-insulin-pump/aw-1005628_c_user-guide-tslim-x2-control-iq-7-4-mgdl-artwork.pdf?sfvrsn=18a507d7_140
[84] Medtronic. MiniMed™ 670G System.
https://www.medtronicdiabetes.com/download-library/minimed-670g-system
[85] OmniPod User Guide.
https://www.omnipod.com/sites/default/files/2021-04/Omnipod-DASH_User-Guide_English.pdf
[86] Medtronic MiniMed™ 640G System User Guide.
https://hcp.medtronic-diabetes.com.au/sites/default/files/minimed-640g-system-user-guide-mmol.pdf
[87] Siebenhofer, A., Jeitler, K., Berghold, A., Horvath, K. and Pieber, T.R. (2009) Severe Hypoglycaemia and Glycaemic Control in Type 1 Diabetes: Meta-Analysis of Multiple Daily Insulin Injections Compared with Continuous Subcutaneous Insulin Infusion. Diabetic Medicine, 26, 311-312; author reply 312-313.
[88] Haynes, E., Ley, M., Talbot, P., Dunbar, M. and Cummings, E. (2021) Insulin Pump Therapy Improves Quality of Life of Young Patients with Type 1 Diabetes Enrolled in a Government-Funded Insulin Pump Program: A Qualitative Study. The Canadian Journal of Diabetes, 45, 395-402.
[89] Al Shaikh, A., Al Zahrani, A.M., Qari, Y.H., AbuAlnasr, A.A., Alhawsawi, W.K., Alshehri, K.A. and AlShaikh, S.A. (2020) Quality of Life in Children with Diabetes Treated with Insulin Pump Compared with Multiple Daily Injections in Tertiary Care Center. Clinical Medicine Insights: Endocrinology and Diabetes, 13.
[90] Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., et al. (2017) A Cluster Randomised Trial, Cost-Effectiveness Analysis and Psychosocial Evaluation of Insulin Pump Therapy Compared with Multiple Injections during Flexible Intensive Insulin Therapy for Type 1 Diabetes: The REPOSE Trial. Health Technology Assessment (Winchester, England), 21.
https://doi.org/10.3310/hta21200
[91] Pańkowska, E., Szypowska, A., Lipka, M., Szpotańska, M., Błazik, M. and Groele, L. (2009) Application of Novel Dual Wave Meal Bolus and Its Impact on Glycated Hemoglobin A1c Level in Children with Type 1 Diabetes. Pediatric Diabetes, 10, 298-303.
[92] Dos Santos, T.J., Donado Campos, J.M., Argente, J. and Rodríguez-Artalejo, F. (2021) Effectiveness and Equity of Continuous Subcutaneous Insulin Infusions in Pediatric Type 1 Diabetes: A Systematic Review and Meta-Analysis of the Literature. Diabetes Research and Clinical Practice, 172, Article ID: 108643.
https://doi.org/10.1016/j.diabres.2020.108643
[93] Monami, M., Lamanna, C., Marchionni, N. and Mannucci, E. (2010) Continuous Subcutaneous Insulin Infusion versus Multiple Daily Insulin Injections in Type 1 Diabetes: A Meta-Analysis. Acta Diabetologica, 47, 77-81.
[94] Zhang, Y., Li, S., Zou, Y., Wu, X., Bi, Y., Zhang, L., Yuan, Y., Gong, W. and Hayter, M. (2021) Fear of Hypoglycemia in Patients with Type 1 and 2 Diabetes: A Systematic Review. Journal of Clinical Nursing, 30, 72-82.
https://doi.org/10.1111/jocn.15538
[95] Barnard, K., Thomas, S., Royle, P., Noyes, K. and Waugh, N. (2010) Fear of Hypoglycaemia in Parents of Young Children with Type 1 Diabetes: A Systematic Review. BMC Pediatrics, 10, Article No. 50.
https://doi.org/10.1186/1471-2431-10-50
[96] Schmidt, S., Andersen Nexø, M., Norgaard, O., Willaing, I., Pedersen-Bjergaard, U., Skinner, T.C. and Nørgaard, K. (2020) Psychosocial Factors Associated with HbA1c in Adults with Insulin Pump-Treated Type 1 Diabetes: A Systematic Review. Diabetic Medicine, 37, 1454-1462.
https://doi.org/10.1111/dme.14347
[97] MiniMed® Veo™ Paradigm™ System.
https://www.medtronic-diabetes.com.au/sites/default/files/veo-step-by-step-guide-fa3-view.pdf
[98] Agrawal, P., Welsh, J.B., Kannard, B., Askari, S., Yang, Q. and Kaufman, F.R. (2011) Usage and Effectiveness of the Low Glucose Suspend Feature of the Medtronic Paradigm Veo Insulin Pump. Journal of Diabetes Science and Technology, 5, 1137-1141.
[99] Choudhary, P., Shin, J., Wang, Y., Evans, M.L., Hammond, P.J., Kerr, D., Shaw, J.A., Pickup, J.C. and Amiel, S.A. (2011) Insulin Pump Therapy with Automated Insulin Suspension in Response to Hypoglycemia: Reduction in Nocturnal Hypoglycemia in Those at Greatest Risk. Diabetes Care, 34, 2023-2025.
[100] Basal IQ User Guide.
https://www.tandemdiabetes.com/docs/default-source/product-documents/t-slim-x2-insulin-pump/aw-1006684_c-user-guide-tslim-x2-basal-iq-6-4-mmoll-artwork-web.pdf?sfvrsn=eeb230d7_139
[101] Medtronic MiniMed™ 640G System User Guide.
[102] Beato-Víbora, P.I., Gil-Poch, E., Galán-Bueno, L., Lázaro-Martín, L. and Arroyo-Díez, F.J. (2018) The Incremental Benefits of the Predictive Low-Glucose Suspend Function Compared to the Low-Glucose Suspend Function as Automation Against Hypoglycemia in Sensor-Augmented Pump Therapy. Journal of Diabetes Science and Technology, 12, 1241-1243.
[103] Kovatchev, B. (2018) Automated Closed-Loop Control of Diabetes: The Artificial Pancreas. Bioelectronic Medicine, 4, Article No. 14.
[104] Medtronic. MiniMed™ 770G System.
[105] Garg, S.K., Weinzimer, S.A., Tamborlane, W.V., Buckingham, B.A., Bode, B.W., Bailey, T.S., Brazg, R.L., Ilany, J., Slover, R.H., Anderson, S.M., et al. (2017) Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics, 19, 155-163.
[106] Forlenza, G.P., Pinhas-Hamiel, O., Liljenquist, D.R., Shulman, D.I., Bailey, T.S., Bode, B.W., Wood, M.A., Buckingham, B.A., Kaiserman, K.B., Shin, J., et al. (2019) Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes. Diabetes Technology & Therapeutics, 21, 11-19.
[107] Collyns, O.J., Meier, R.A., Betts, Z.L., Chan, D.S.H., Frampton, C., Frewen, C.M., Hewapathirana, N.M., Jones, S.D., Roy, A., Grosman, B., et al. (2021) Improved Glycemic Outcomes with Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results from a Randomized Crossover Trial Comparing Automated Insulin Delivery with Predictive Low Glucose Suspend in People with Type 1 Diabetes. Diabetes Care, 44, 969-975.
https://doi.org/10.2337/figshare.13618910.v1
[108] Bergenstal, R.M., Nimri, R., Beck, R.W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S.A., Sibayan, J., et al. (2021) A Comparison of Two Hybrid Closed-Loop Systems in Adolescents and Young Adults with Type 1 Diabetes (FLAIR): A Multicentre, Randomised, Crossover Trial. The Lancet, 397, 208-219.
[109] Messer, L.H., Berget, C., Vigers, T., Pyle, L., Geno, C., Wadwa, R.P., Driscoll, K.A. and Forlenza, G.P. (2020) Real World Hybrid Closed-Loop Discontinuation: Predictors and Perceptions of Youth Discontinuing the 670G System in the First 6 Months. Pediatric Diabetes, 21, 319-327.
[110] Lal, R.A., Basina, M., Maahs, D.M., Hood, K., Buckingham, B. and Wilson, D.M. (2019) One Year Clinical Experience of the First Commercial Hybrid Closed-Loop. Diabetes Care, 42, 2190-2196.
[111] Brown, S.A., Kovatchev, B.P., Raghinaru, D., Lum, J.W., Buckingham, B.A., Kudva, Y.C., Laffel, L.M., Levy, C.J., Pinsker, J.E., Wadwa, R.P., et al. (2019) Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. The New England Journal of Medicine, 381, 1707-1717.
https://doi.org/10.1056/NEJMoa1907863
[112] Breton, M.D., Kanapka, L.G., Beck, R.W., Ekhlaspour, L., Forlenza, G.P., Cengiz, E., Schoelwer, M., Ruedy, K.J., Jost, E., Carria, L., et al. (2020) A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. The New England Journal of Medicine, 383, 836-845.
[113] Breton, M.D. and Kovatchev, B.P. (2021) One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technology & Therapeutics, 23, 601-608.
[114] Brown, S.A., Forlenza, G.P., Bode, B.W., Pinsker, J.E., Levy, C.J., Criego, A.B., Hansen, D.W., Hirsch, I.B., Carlson, A.L., Bergenstal, R.M., et al. (2021) Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System with Customizable Glycemic Targets in Pediatric and Adult Participants with Type 1 Diabetes. Diabetes Care, 44, 1630-1640.
[115] Sherr, J.L., Buckingham, B.A., Forlenza, G.P., Galderisi, A., Ekhlaspour, L., Wadwa, R.P., Carria, L., Hsu, L., Berget, C., Peyser, T.A., et al. (2020) Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes over 5 Days under Free-Living Conditions. Diabetes Technology & Therapeutics, 22, 174-184.
[116] Buckingham, B.A., Forlenza, G.P., Pinsker, J.E., Christiansen, M.P., Wadwa, R.P., Schneider, J., Peyser, T.A., Dassau, E., Lee, J.B., O'Connor, J., et al. (2018) Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes Technology & Therapeutics, 20, 257-262.
[117] CamAPS FX User Manual.
https://s3-eu-west-1.amazonaws.com/camdiab.user.manual/user_manual_fx_mmoll_commercial.pdf
[118] Leelarathna, L., Choudhary, P., Wilmot, E.G., Lumb, A., Street, T., Kar, P. and Ng, S.M. (2021) Hybrid Closed-Loop Therapy: Where Are We in 2021? Diabetes, Obesity & Metabolism, 23, 655-660.
[119] Chen, N.S., Boughton, C.K., Hartnell, S., Fuchs, J., Allen, J.M., Willinska, M.E., Thankamony, A., de Beaufort, C., Campbell, F.M., Fröhlich-Reiterer, E., et al. (2021) User Engagement with the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics. Diabetes Care, 44, e148-e150.
[120] Thabit, H., Tauschmann, M., Allen, J.M., Leelarathna, L., Hartnell, S., Wilinska, M.E., Acerini, C.L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) Home Use of an Artificial Beta Cell in Type 1 Diabetes. The New England Journal of Medicine, 373, 2129-2140.
[121] Amadou, C., Franc, S., Benhamou, P.Y., Lablanche, S., Huneker, E., Charpentier, G. and Penfornis, A. (2021) Diabeloop DBLG1 Closed-Loop System Enables Patients with Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations without Serious Adverse Events: 6-Month Follow-Up. Diabetes Care, 44, 844-846.
[122] Benhamou, P.Y., Huneker, E., Franc, S., Doron, M. and Charpentier, G. (2018) Customization of Home Closed-Loop Insulin Delivery in Adult Patients with Type 1 Diabetes, Assisted with Structured Remote Monitoring: The Pilot WP7 Diabeloop Study. Acta Diabetologica, 55, 549-556.
[123] Viñals, C., Beneyto, A., Martín-SanJosé, J.F., Furió-Novejarque, C., Bertachi, A., Bondia, J., Vehi, J., Conget, I. and Giménez, M. (2021) Artificial Pancreas with Carbohydrate Suggestion Performance for Unannounced and Announced Exercise in Type 1 Diabetes. The Journal of Clinical Endocrinology and Metabolism, 106, 55-63.
https://doi.org/10.1210/clinem/dgaa562
[124] Omer, T. (2016) Empowered Citizen "Health Hackers" Who Are Not Waiting. BMC Medicine, 14, Article No. 118.
[125] Loop and Learn—FreeAPS.
https://www.loopnlearn.org/freeapsdoc/
[126] Kesavadev, J., Srinivasan, S., Saboo, B., Krishna, B.M. and Krishnan, G. (2020) The Do-It-Yourself Artificial Pancreas: A Comprehensive Review. Diabetes Therapy, 11, 1217-1235.
https://doi.org/10.1007/s13300-020-00823-z
[127] OpenAPS Outcomes.
https://openaps.org/outcomes/
[128] Lum, J. (2020) Loop Observational Study—Evaluating Do-It-Yourself (DIY) Automated Insulin Delivery. ATTD 2020, Madrid.
[129] Tidepool iAC.
https://www.tidepool.org/blog/interoperability-is-the-how-not-the-why
[130] Toffanin, C., Kozak, M., Sumnik, Z., Cobelli, C. and Petruzelkova, L. (2020) In Silico Trials of an Open-Source Android-Based Artificial Pancreas: A New Paradigm to Test Safety and Efficacy of Do-It-Yourself Systems. Diabetes Technology & Therapeutics, 22, 112-120.
[131] Jennings, P. and Hussain, S. (2020) Do-It-Yourself Artificial Pancreas Systems: A Review of the Emerging Evidence and Insights for Healthcare Professionals. Journal of Diabetes Science and Technology, 14, 868-877.
[132] Mack, G.S. (2007) Pfizer Dumps Exubera. Nature Biotechnology, 25, 1331-1332.
https://doi.org/10.1038/nbt1207-1331
[133] Afrezza Prescribing Information.
https://www.afrezza.com/pdf/Full-Prescribing-Information.pdf
[134] Gerber, R.A., Cappelleri, J.C., Kourides, I.A. and Gelfand, R.A. (2001) Treatment Satisfaction with Inhaled Insulin in Patients with Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care, 24, 1556-1559.
https://doi.org/10.2337/diacare.24.9.1556
[135] Royle, P., Waugh, N., McAuley, L., McIntyre, L. and Thomas, S. (2003) Inhaled Insulin in Diabetes Mellitus. Cochrane Database of Systematic Reviews, 2003, CD003890.
[136] Pittas, A.G., Westcott, G.P. and Balk, E.M. (2015) Efficacy, Safety, and Patient Acceptability of Technosphere Inhaled Insulin for People with Diabetes: A Systematic Review and Meta-Analysis. The Lancet Diabetes & Endocrinology, 3, 886-894.
[137] Galderisi, A., Cohen, N., Calhoun, P., Kraemer, K., Breton, M., Weinzimer, S. and Cengiz, E. (2020) Effect of Afrezza on Glucose Dynamics during HCL Treatment. Diabetes Care, 43, 2146-2152.
[138] Santos, L.L., Lima, F.J.C., Sousa-Rodrigues, C.F. and Barbosa, F.T. (2017) Use of SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Revista da Associacao Medica Brasileira, 63, 636-641.
https://doi.org/10.1590/1806-9282.63.07.636
[139] Buse, J.B., Garg, S.K., Rosenstock, J., Bailey, T.S., Banks, P., Bode, B.W., Danne, T., Kushner, J.A., Lane, W.S., Lapuerta, P., et al. (2018) Sotagliflozin in Combination with Optimized Insulin Therapy in Adults with Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care, 41, 1970-1980.
[140] Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschope, D., Thoren, F., Xu, J. and Langkilde, A.M. (2018) Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 41, 2552-2559.
[141] Rosenstock, J., Marquard, J., Laffel, L.M., Neubacher, D., Kaspers, S., Cherney, D.Z., Zinman, B., Skyler, J.S., George, J., Soleymanlou, N., et al. (2018) Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care, 41, 2560-2569.
[142] Yu, X., Zhang, S. and Zhang, L. (2018) Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. International Journal of Endocrinology, 2018, Article ID: 7074868.
[143] Lu, J., Tang, L., Meng, H., Zhao, J. and Liang, Y. (2019) Effects of Sodium-Glucose Cotransporter (SGLT) Inhibitors in Addition to Insulin Therapy on Glucose Control and Safety Outcomes in Adults with Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Diabetes/Metabolism Research and Reviews, 35, e3169.
https://doi.org/10.1002/dmrr.3169
[144] Teymourian, H., Moonla, C., Tehrani, F., Vargas, E., Aghavali, R., Barfidokht, A., Tangkuaram, T., Mercier, P.P., Dassau, E. and Wang, J. (2020) Microneedle-Based Detection of Ketone Bodies along with Glucose and Lactate: Toward Real-Time Continuous Interstitial Fluid Monitoring of Diabetic Ketosis and Ketoacidosis. Analytical Chemistry, 92, 2291-2300.
https://doi.org/10.1021/acs.analchem.9b05109
[145] Flores, M., Amir, M., Ahmed, R., Alashi, S., Li, M., Wang, X., Lansang, M.C. and Al-Jaghbeer, M.J. (2020) Causes of Diabetic Ketoacidosis among Adults with Type 1 Diabetes Mellitus: Insulin Pump Users and Non-Users. BMJ Open Diabetes & Research Care, 8, e001329.
[146] Miller, E., Doshi, A., Grøn, R., Jódar, E., Őrsy, P., Ranthe, M.F., Sugimoto, D., Tentolouris, N., Viljoen, A. and Billings, L.K. (2019) IDegLira Improves Patient-Reported Outcomes While Using a Simple Regimen with Fewer Injections and Dose Adjustments Compared with Basal-Bolus Therapy. Diabetes, Obesity & Metabolism, 21, 2643-2650.
[147] Rosenstock, J., Bajaj, H.S., Janež, A., Silver, R., Begtrup, K., Hansen, M.V., Jia, T. and Goldenberg, R. (2020) Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. The New England Journal of Medicine, 383, 2107-2116.
[148] Ozer, K., Cooper, A.M., Ahn, L.P., Waggonner, C.R. and Blevins, T.C. (2021) Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study. Diabetes Technology & Therapeutics, 23, 286-292.
[149] Grosman, B., Wu, D., Parikh, N., Roy, A., Voskanyan, G., Kurtz, N., Sturis, J., Cohen, O., Ekelund, M. and Vigersky, R. (2021) Fast-Acting Insulin Aspart (Fiasp®) Improves Glycemic Outcomes When Used with MiniMed(TM) 670G Hybrid Closed-Loop System in Simulated Trials Compared to NovoLog®. Computer Methods and Programs in Biomedicine, 205, Article ID: 106087.
https://doi.org/10.1016/j.cmpb.2021.106087
[150] Hsu, L., Buckingham, B., Basina, M., Ekhlaspour, L., von Eyben, R., Wang, J. and Lal, R.A. (2021) Fast-Acting Insulin Aspart Use with the MiniMed™ 670G System. Diabetes Technology & Therapeutics, 23, 1-7.
[151] Boughton, C.K., Hartnell, S., Thabit, H., Poettler, T., Herzig, D., Wilinska, M.E., Ashcroft, N.L., Sibayan, J., Cohen, N., Calhoun, P., Bally, L., et al. (2021) Hybrid Closed-Loop Glucose Control with Faster Insulin Aspart Compared with Standard Insulin Aspart in Adults with Type 1 Diabetes: A Double-Blind, Multicentre, Multinational, Randomized, Crossover Study. Diabetes, Obesity & Metabolism, 23, 1389-1396.
[152] Tsoukas, M.A., Cohen, E., Legault, L., von Oettingen, J.E., Yale, J.F., Vallis, M., Odabassian, M., El Fathi, A., Rutkowski, J., Jafar, A., et al. (2021) Alleviating Carbohydrate Counting with a FiASP-plus-Pramlintide Closed-Loop Delivery System (Artificial Pancreas): Feasibility and Pilot Studies. Diabetes, Obesity & Metabolism, 23, 2090-2098.
[153] OpenAPS.
https://openaps.readthedocs.io/en/latest/docs/Customize-Iterate/oref1.html#understanding-unannounced-meals-uam
[154] Pohl, R., Li, M., Krasner, A. and De Souza, E. (2015) Development of Stable Liquid Glucagon Formulations for Use in Artificial Pancreas. Journal of Diabetes Science and Technology, 9, 8-16.
[155] Castle, J.R., Youssef, J.E., Branigan, D., Newswanger, B., Strange, P., Cummins, M., Shi, L. and Prestrelski, S. (2016) Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon versus Lyophilized Glucagon in Type 1 Diabetes Subjects. Journal of Diabetes Science and Technology, 10, 1101-1107.
[156] Blair, H.A. (2021) Dasiglucagon: First Approval. Drugs, 81, 1115-1120.
[157] Taleb, N., Emami, A., Suppere, C., Messier, V., Legault, L., Ladouceur, M., Chiasson, J.L., Haidar, A. and Rabasa-Lhoret, R. (2016) Efficacy of Single-Hormone and Dual-Hormone Artificial Pancreas during Continuous and Interval Exercise in Adult Patients with Type 1 Diabetes: Randomised Controlled Crossover Trial. Diabetologia, 59, 2561-2571.
[158] Castle, J.R., El Youssef, J., Wilson, L.M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors. Diabetes Care, 41, 1471-1477.
[159] Haidar, A., Legault, L., Messier, V., Mitre, T.M., Leroux, C. and Rabasa-Lhoret, R. (2015) Comparison of Dual-Hormone Artificial Pancreas, Single-Hormone Artificial Pancreas, and Conventional Insulin Pump Therapy for Glycaemic Control in Patients with Type 1 Diabetes: An Open-Label Randomised Controlled Crossover Trial. The Lancet Diabetes & Endocrinology, 3, 17-26.
[160] Russell, S.J., Hillard, M.A., Balliro, C., Magyar, K.L., Selagamsetty, R., Sinha, M., Grennan, K., Mondesir, D., Ekhlaspour, L., Zheng, H., et al. (2016) Day and Night Glycaemic Control with a Bionic Pancreas versus Conventional Insulin Pump Therapy in Preadolescent Children with Type 1 Diabetes: A Randomised Crossover Trial. The Lancet Diabetes & Endocrinology, 4, 233-243.
[161] Castellanos, L.E., Balliro, C.A., Sherwood, J.S., Jafri, R., Hillard, M.A., Greaux, E., Selagamsetty, R., Zheng, H., El-Khatib, F.H., Damiano, E.R., et al. (2021) Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults with Type 1 Diabetes in a Home-Use Setting. Diabetes Care, 44, e118-e120.
[162] Wilson, L.M., Jacobs, P.G., Ramsey, K.L., Resalat, N., Reddy, R., Branigan, D., Leitschuh, J., Gabo, V., Guillot, F., et al. (2020) Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation versus Insulin-Only Closed-Loop System Compared with a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial. Diabetes Care, 43, 2721-2729.
[163] El-Khatib, F.H., Balliro, C., Hillard, M.A., Magyar, K.L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M.J., et al. (2017) Home Use of a Bihormonal Bionic Pancreas versus Insulin Pump Therapy in Adults with Type 1 Diabetes: A Multicentre Randomised Crossover Trial. The Lancet, 389, 369-380.
[164] Peters, T.M. and Haidar, A. (2018) Dual-Hormone Artificial Pancreas: Benefits and Limitations Compared with Single-Hormone Systems. Diabetic Medicine, 35, 450-459.
[165] Sherr, J.L., Patel, N.S., Michaud, C.I., Palau-Collazo, M.M., Van Name, M.A., Tamborlane, W.V., Cengiz, E., Carria, L.R., Tichy, E.M. and Weinzimer, S.A. (2016) Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner during Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care, 39, 1127-1134.
[166] Mathieu, C., Zinman, B., Hemmingsson, J.U., Woo, V., Colman, P., Christiansen, E., Linder, M. and Bode, B. (2016) Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-to-Target Randomized Trial. Diabetes Care, 39, 1702-1710.
[167] Dejgaard, T.F., Frandsen, C.S., Hansen, T.S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A.K., Holst, J.J., Tarnow, L., et al. (2016) Efficacy and Safety of Liraglutide for Overweight Adult Patients with Type 1 Diabetes and Insufficient Glycaemic Control (Lira-1): A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Diabetes & Endocrinology, 4, 221-232.
[168] Riddell, M.C., Gallen, I.W., Smart, C.E., Taplin, C.E., Adolfsson, P., Lumb, A.N., Kowalski, A., Rabasa-Lhoret, R., McCrimmon, R.J., Hume, C., et al. (2017) Exercise Management in Type 1 Diabetes: A Consensus Statement. The Lancet Diabetes & Endocrinology, 5, 377-390.
[169] Ploug, T., Galbo, H. and Richter, E.A. (1984) Increased Muscle Glucose Uptake during Contractions: No Need for Insulin. The American Journal of Physiology, 247, E726-E731.
https://doi.org/10.1152/ajpendo.1984.247.6.E726
[170] Hawley, J.A. and Lessard, S.J. (2008) Exercise Training-Induced Improvements in Insulin Action. Acta Physiologica, 192, 127-135.
[171] Jacobs, P.G., El Youssef, J., Reddy, R., Resalat, N., Branigan, D., Condon, J., Preiser, N., Ramsey, K., Jones, M., Edwards, C., et al. (2016) Randomized Trial of a Dual-Hormone Artificial Pancreas with Dosing Adjustment during Exercise Compared with No Adjustment and Sensor-Augmented Pump Therapy. Diabetes, Obesity & Metabolism, 18, 1110-1119.
[172] Resalat, N., El Youssef, J., Reddy, R. and Jacobs, P.G. (2016) Design of a Dual-Hormone Model Predictive Control for Artificial Pancreas with Exercise Model. 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Orlando, FL, 16-20 August 2016, 2270-2273.
https://doi.org/10.1109/EMBC.2016.7591182
[173] Jayawardene, D.C., McAuley, S.A., Horsburgh, J.C., Gerche, A., Jenkins, A.J., Ward, G.M., MacIsaac, R.J., Roberts, T.J., Grosman, B., et al. (2017) Closed-Loop Insulin Delivery for Adults with Type 1 Diabetes Undertaking High-Intensity Interval Exercise versus Moderate-Intensity Exercise: A Randomized, Crossover Study. Diabetes Technology & Therapeutics, 19, 340-348.
[174] Breton, M.D., Brown, S.A., Karvetski, C.H., Kollar, L., Topchyan, K.A., Anderson, S.M. and Kovatchev, B.P. (2014) Adding Heart Rate Signal to a Control-to-Range Artificial Pancreas System Improves the Protection against Hypoglycemia during Exercise in Type 1 Diabetes. Diabetes Technology & Therapeutics, 16, 506-511.
[175] Lee, M.H., Paldus, B., Krishnamurthy, B., McAuley, S.A., Shah, R., Jenkins, A.J. and O'Neal, D.N. (2019) The Clinical Case for the Integration of a Ketone Sensor as Part of a Closed Loop Insulin Pump System. Journal of Diabetes Science and Technology, 13, 967-973.
[176] Alva, S., Castorino, K., Cho, H. and Ou, J. (2021) Feasibility of Continuous Ketone Monitoring in Subcutaneous Tissue Using a Ketone Sensor. Journal of Diabetes Science and Technology, 15, 768-774.
[177] O'Connor, M.R., Carlin, K., Coker, T., Zierler, B. and Pihoker, C. (2019) Disparities in Insulin Pump Therapy Persist in Youth with Type 1 Diabetes Despite Rising Overall Pump Use Rates. Journal of Pediatric Nursing, 44, 16-21.
https://doi.org/10.1016/j.pedn.2018.10.005
[178] Renard, E., Tubiana-Rufi, N., Bonnemaison-Gilbert, E., Coutant, R., Dalla-Vale, F., Farret, A., Poidvin, A., Bouhours-Nouet, N., Abettan, C., Storey-London, C., et al. (2019) Closed-Loop Driven by Control-to-Range Algorithm Outperforms Threshold-Low-Glucose-Suspend Insulin Delivery on Glucose Control Albeit Not on Nocturnal Hypoglycaemia in Prepubertal Patients with Type 1 Diabetes in a Supervised Hotel Setting. Diabetes, Obesity & Metabolism, 21, 183-187.
[179] American Diabetes Association. Help with Insulin Is a Phone Call Away.
https://insulinhelp.org
[180] Shafie, A.A., Ng, C.H., Tan, Y.P. and Chaiyakunapruk, N. (2017) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. Pharmacoeconomics, 35, 141-162.
[181] Walker, A.F., Hood, K.K., Gurka, M.J., Filipp, S.L., Anez-Zabala, C., Cuttriss, N., Haller, M.J., Roque, X., Naranjo, D., Aulisio, G., et al. (2021) Barriers to Technology Use and Endocrinology Care for Underserved Communities with Type 1 Diabetes. Diabetes Care, 44, 1480-1490.
[182] Sumnik, Z., Szypowska, A., Iotova, V., Bratina, N., Cherubini, V., Forsander, G., Jali, S., Raposo, J.F., Stipančic, G., Vazeou, A., et al. (2019) Persistent Heterogeneity in Diabetes Technology Reimbursement for Children with Type 1 Diabetes: The SWEET Perspective. Pediatric Diabetes, 20, 434-443.
[183] Lipman, T.H., Smith, J.A., Patil, O., Willi, S.M. and Hawkes, C.P. (2021) Racial Disparities in Treatment and Outcomes of Children with Type 1 Diabetes. Pediatric Diabetes, 22, 241-248.
[184] Fantasia, K.L., Wirunsawanya, K., Lee, C. and Rizo, I. (2021) Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital. Journal of Diabetes Science and Technology, 15, 1010-1017.
[185] Walker, A.F., Haller, M.J., Gurka, M.J., Morris, H.L., Bruggeman, B., Miller, K., Foster, N., Anez Zabala, C. and Schatz, D.A. (2020) Addressing Health Disparities in Type 1 Diabetes through Peer Mentorship. Pediatric Diabetes, 21, 120-127.
[186] Peters, A.L. and Garg, S.K. (2020) The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth. Diabetes Technology & Therapeutics, 22, 449-453.
JDM Subscription


Directions: Smash Cilantro in the old fashioned glass. Mix in all other ingredients and shake well with ice cubes. Add little amount of soda water before serve.
Comment: Asian Cilantro Mojito. Asian customer will love this for sure.


As our Las Vegas team competes, we will be honoring Geoffery Scott Schelin, one of our team member's uncles who gave the ultimate sacrifice on the USS Iowa. He was one of 47 sailors that died when a gun turret exploded wile they were at sea on April 19,1989.
Show your support with a Las Vegas GRIMP NA shirt today!


text:
Q: Proof that $\mathbb{C}[x,(x-\lambda)^{-1}]$ is a finitely-generated left $A_1(\mathbb{C})$-module I want to prove  that $\mathbb{C}[x,(x-\lambda)^{-1}]$ is a finitely-generated left $A_1(\mathbb{C})$-module where $\lambda \in \mathbb{C}$ and $\mathbb{C}[x,(x-\lambda)^{-1}]$ is a subring of $\mathbb{C}(x)$. So far I know that for a left $R$-module $M$ over a left noetherian ring; $M$ is noetherian $\iff$ $M$ is a finitely-generated $R$-module, and that $M$ is noetherian $\iff$ $N$ and $M/N$ are noetherian where $N$ is a submodule of $M$.
I was hoping to use this with $M=\mathbb{C}[x,(x-\lambda)^{-1}]$ and $N = \mathbb{C}[x]$ as I know $\mathbb{C}[x]$ is noetherian by HBT and $A_1(\mathbb{C})$ is also noetherian. The question also mentions that I can assume that $\mathbb{C}(x)$ is a left $A_1(\mathbb{C})$-module but I'm not sure how that helps. Any help will be appreciated :)

A: You are making this way more complicated than necessary.  To prove $\mathbb{C}[x,(x-\lambda)^{-1}]$ is finitely generated, you can just find a finite set of generators.  To do this, you just need to understand the action of $A_1(\mathbb{C})$: $A_1(\mathbb{C})$ is generated as a $\mathbb{C}$-algebra by elements which act on $\mathbb{C}(x)$ by multiplication by $x$ and by differentiation.  So you just have to find finitely many elements of $\mathbb{C}[x,(x-\lambda)^{-1}]$ which generate everything with respect to the operations of multiplication by $x$, differentiation, and taking $\mathbb{C}$-linear combinations.
Since every element of $\mathbb{C}[x,(x-\lambda)^{-1}]$ is a $\mathbb{C}$-linear combination of a power of $x$ times a power of $(x-\lambda)^{-1}$, we just need a finite set that generates all the powers of $(x-\lambda)^{-1}$.  Now we observe that if we differentiate $(x-\lambda)^{-1}$ $n$ times, we get a nonzero scalar multiple of $(x-\lambda)^{-1-n}$.  So, $(x-\lambda)^{-1}$ alone already generates all the positive powers of $(x-\lambda)^{-1}$, and so $\{1,(x-\lambda)^{-1}\}$ generates the entire module. (In fact, it is not necessarily to include $1$, since it is $x\cdot (x-\lambda)^{-1}-\lambda\cdot(x-\lambda)^{-1}$.)

redpajama_set_name: RedPajamaStackExchange